<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866512</url>
  </required_header>
  <id_info>
    <org_study_id>250839</org_study_id>
    <nct_id>NCT03866512</nct_id>
  </id_info>
  <brief_title>Forearm Immobilization, Metabolic Health, and Muscle Loss</brief_title>
  <official_title>The Impact of Acipimox and Salbutamol Supplementation on the Development of Insulin Resistance and Anabolic Resistance During Forearm Immobilization in Healthy, Young Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Exeter</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will investigate the impact of altered substrate availability on muscle&#xD;
      atrophy, insulin sensitivity and muscle protein synthesis following short-term forearm&#xD;
      immobilization&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty-six healthy young volunteers will undergo 2 days of forearm immobilization combined&#xD;
      with ingestion of one of two drug or placebo. Before and after immobilization, they will&#xD;
      receive a stable isotope tracer infusion (5.5 h) combined with repeated blood and muscle&#xD;
      sampling under insulin clamp conditions, in order to measure insulin sensitivity and muscle&#xD;
      protein synthesis in the fasted and fed state.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind study design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Forearm glucose uptake</measure>
    <time_frame>During the steady-state phase of the insulin clamp (i.e. last 30 min)</time_frame>
    <description>Insulin sensitivity, measured as forearm glucose uptake, under hyperinsulinaemic-euglycaemic conditions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle protein synthesis</measure>
    <time_frame>In the fasted state (30 min before starting insulin clamp), and during the steady-state phase of the insulin clamp (i.e. last 30 min)</time_frame>
    <description>Muscle protein synthesis, measured as using the arteriovenous-venous method, via stable isotope tracer infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forearm muscle volume</measure>
    <time_frame>Following cast application, and immediately after 2 days of forearm immobilizaiton</time_frame>
    <description>Forearm muscle volume measured via MRI</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Acipimox ingestion during immobilization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ingestion of Acipimox during 2 days of forearm immobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-agonist during immobilization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ingestion of salbutamol during 2 days of forearm immobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo ingestion during immobilization</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral ingestion of a placebo 2 days of forearm immobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Forearm immobilization</intervention_name>
    <description>Two days of forearm immobilization</description>
    <arm_group_label>Acipimox ingestion during immobilization</arm_group_label>
    <arm_group_label>B-agonist during immobilization</arm_group_label>
    <arm_group_label>Placebo ingestion during immobilization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18-40 years of age&#xD;
&#xD;
          -  Body mass index between 18 and 27&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any diagnosed metabolic impairment (e.g. type 1 or 2 diabetes)&#xD;
&#xD;
          -  Any diagnosed cardiovascular disease&#xD;
&#xD;
          -  Hypertension (≥140 mmHg systolic and/or ≥90 mmHg diastolic)&#xD;
&#xD;
          -  Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral&#xD;
             contraceptives and contraceptive devices)&#xD;
&#xD;
          -  Regular use of nutritional supplements&#xD;
&#xD;
          -  Metallic implants&#xD;
&#xD;
          -  A personal or family history of thrombosis, epilepsy, seizures or schizophrenia&#xD;
&#xD;
          -  Any previous motor disorders&#xD;
&#xD;
          -  Any known disorders in lipid metabolism&#xD;
&#xD;
          -  Any known disorders in muscle metabolism&#xD;
&#xD;
          -  Known allergy for Acipimox, beta agonist, or other substances in the tablets&#xD;
&#xD;
          -  Known sensitivity for sympathomimetic drugs&#xD;
&#xD;
          -  Known hypokalaemia&#xD;
&#xD;
          -  Presence of an ulcer in the stomach or gut and/or strong history of indigestion&#xD;
&#xD;
          -  Known severe kidney problems&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlou Dirks, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Exeter &amp; Devon NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

